Symbols

FMS

Fresenius Medical·NYSE

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

Bullish Abandoned Baby

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FMS

Fresenius Medical Care Ag

The nation's leading provider of kidney care services

Industry

Healthcare Providers and Services

Established Date

08/05/1996

Listing Date

10/01/1996

Exchange

New York Stock Exchange

Full-time Employees

109,698

Fiscal Year Ends

12-31

Website

www.freseniusmedicalcare.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Else-Kroner Strasse 1, 61352 Bad Homburg, Germany

Business

Introduction

Fresenius Medical Care AG was originally established as a joint stock company on August 5, 1996 and registered as a joint stock company on February 10, 2006. The company is the world's leading provider of products and services for patients with kidney disease. As a vertically integrated medical technology (MedTech) and medical services company, Fresenius Medical Care combines medical device engineering and manufacturing expertise with comprehensive patient care. In three operating segments, care delivery (CD), value-based care (VBC) and care support (CE), the company provides a full range of medical services, systems, devices, technologies, products and pharmaceuticals to provide high-quality care for kidney disease patients worldwide.

Company Financials

EPS

FMS has released its 2023 Q4 earnings. EPS was reported at 0.47, versus the expected 0.32, beating expectations. The chart below visualizes how FMS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FMS has released its 2025 Q4 earnings report, with revenue of 5.95B, reflecting a YoY change of 13.04%, and net profit of 471.81M, showing a YoY change of 285.90%. The Sankey diagram below clearly presents FMS's revenue sources and cost distribution.